In a report published Monday, Morgan Stanley reiterated its Equal-Weight rating on Sagent Pharmaceuticals (NASDAQ: SGNT ). Morgan Stanley noted, “Total November IMS sales were $17MM establishing a 4Q12 run rate of $53MM in-line with MSe and Cns of $52MM and guidance of ~$50MM. However, the focus is now on